- Home
- FLC vs CHRS Comparison
FLC vs CHRS Comparison
Compare FLC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | CHRS |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.5M | 186.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | FLC | CHRS |
|---|---|---|
| Price | $17.47 | $1.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.02 |
| AVG Volume (30 Days) | 37.8K | ★ 907.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.34 |
| Revenue | N/A | ★ $277,728,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $67.29 |
| P/E Ratio | ★ N/A | $0.99 |
| Revenue Growth | N/A | ★ 152.07 |
| 52 Week Low | $12.62 | $0.71 |
| 52 Week High | $15.45 | $1.89 |
Technical Indicators
Market Signals| Indicator | FLC | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 49.77 |
| Support Level | $17.25 | $1.30 |
| Resistance Level | $17.68 | $1.43 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 24.44 | 59.84 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.